Skip to main content

Advertisement

ADVERTISEMENT

News

News
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
Conference Coverage
09/12/2024
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the...
09/12/2024
Oncology

Advertisement

Conference Coverage
09/12/2024
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the...
09/12/2024
Oncology
Conference Coverage
09/12/2024
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the...
09/12/2024
Oncology
Conference Coverage
09/12/2024
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the...
09/12/2024
Oncology

Advertisement

News
08/29/2024
According to results from a univariable and multivariable analysis, undergoing lymph node dissection at the time of hysterectomy improved overall survival among patients with stage 3 endometrial cancer.
According to results from a univariable and multivariable analysis, undergoing lymph node dissection at the time of hysterectomy improved overall survival among patients with stage 3 endometrial cancer.
According to results from a...
08/29/2024
Oncology
News
08/20/2024
There were no differences found for progression-free survival, overall survival, or surgical complications between minimally invasive or open staging surgeries among patients with non-endometrioid endometrial cancer.
There were no differences found for progression-free survival, overall survival, or surgical complications between minimally invasive or open staging surgeries among patients with non-endometrioid endometrial cancer.
There were no differences found...
08/20/2024
Oncology
News
08/20/2024
According to a prospective longitudinal study, the perceived presence of social support for patients with endometrial who underwent surgery was associated with better quality of life at 1 year post-surgery.
According to a prospective longitudinal study, the perceived presence of social support for patients with endometrial who underwent surgery was associated with better quality of life at 1 year post-surgery.
According to a prospective...
08/20/2024
Oncology

Advertisement

News
08/20/2024
Interim analysis results from the phase 3 AtTEnd trial demonstrated that atezolizumab plus chemotherapy improved progression-free survival among patients with advanced or recurrent endometrial cancer.
Interim analysis results from the phase 3 AtTEnd trial demonstrated that atezolizumab plus chemotherapy improved progression-free survival among patients with advanced or recurrent endometrial cancer.
Interim analysis results from...
08/20/2024
Oncology

Advertisement